They might be senior marketing executives intent on helping their companies develop and sustain breakthrough medical therapies, or biopharma entrepreneurs on the hunt for the right co-promotion partner. They might be portfolio managers on the cusp of a major in-licensing deal, or pricing managers determined to isolate a product’s true market value. They might be consumer health or medical device companies, regulatory authorities, payers, even governments.

They share questions, certainly, but they also share this: A desire to know what IMS thinks.  Clients come to us with multiple needs, and to every challenge we bring an arsenal of proven resources.

We don’t just track information at IMS; we evaluate it, test it, understand it. We take a vast array of healthcare data and facts and transform them into actionable intelligence. By assessing billions of transactions involving more than a million products from 3,000+ pharmaceutical manufacturers, we remain the go-to company for clients seeking to make faster, smarter decisions.

Having spent more than 50 years watching, measuring and analyzing the worldwide pharmaceutical industry, we take the guessing game out of strategic and tactical planning by fortifying our clients with actionable insights. Our information sets are rich, and integrated. They tell stories, suggest new directions.

A real return must be realized on promotional investments. Brands must excel at launch, and continue to soar. IMS helps clients optimize their commercial resources and enhance global planning and implementation.

Regardless of where they are based or which patients they serve, pharmaceutical and biotechnology companies are in the business of getting their products into the hands of those who can benefit most. IMS guides the way.

There’s always the need to generate revenues in the near term — and the imperative for sustaining a healthy pipeline of drugs and other innovations, such as delivery technology and diagnostics. IMS helps clients align portfolios with their strategies, ones that factor resources, product mix and appetite for risk into the equation.

Effectiveness is no longer the standard bearer in healthcare. Value is. Cost-of-illness studies, disease management modules and compliance and persistence analyses must all be factored into the equation. So must the implications of drug safety indicators and risk projections. At IMS, we help clients see a more complete picture, and ensure that product value is proven and communicated to decision makers.

IMS consultants are uniquely positioned to tap the full breadth of our leading-edge analytical methodologies and rich global information assets — providing critical market perspective and solutions that work in the real world.

We apply Evidence-Based Consulting^SM that can have an immediate impact on the business and market performance of our clients. We help to strengthen portfolios, optimize product launches, mount superior marketing efforts, forge more productive alliances and optimize sales force structure and deployment.

With more than four dozen new oncology products set to launch over the next five years, this critical therapeutic class has become a major driver of pharmaceutical market growth.  Our global oncology experts help clients evaluate their options, shape successful strategies for action, and make critical bottom-line decisions. At IMS, we play an integral role in focusing the industry on the therapies that will diminish the ravages of this disease.